Clinical relevance of JAK2 (V617F) mutant allele burden

被引：60
|
作者：
Passamonti, Francesco [1 ]
Rumi, Elisa [1 ]
机构：
[1] Univ Pavia, Fdn IRCCS Policlin San Matteo, Div Hematol, I-27100 Pavia, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷 / 01期
关键词：
POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; WILD-TYPE; MUTATION; JAK2V617F; MYELOFIBROSIS; JAK2(V617F); RISK; PROGRESSION; GRANULOCYTE;
D O I：
10.3324/haematol.2008.001271
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：7 / 10
页数：4
相关论文
共 50 条
  • [31] The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis - impact on disease phenotype
    Larsen, Thomas Stauffer
    Pallisgaard, Niels
    Moller, Michael Boe
    Hasselbalch, Hans Carl
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (06) : 508 - 515
  • [32] Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycthemia vera and essential thrombocythemia
    Trifa, Adrian P.
    Banescu, Claudia
    Voina, Cristian M.
    Popa, Stefana
    Torok-Vistai, Tunde
    Bojan, Anca S.
    Dima, Delia
    Zdrenghea, Mihnea
    Fetica, Bogdan
    Visan, Simona
    Tomuleasa, Ciprian
    Parvu, Andrada
    Urian, Laura
    Pop, Bogdan
    Popov, Viola M.
    Andreescu, Mihaela
    Popp, Radu A.
    BLOOD CELLS MOLECULES AND DISEASES, 2018, 73 : 45 - 46
  • [33] Rapid quantification of JAK2 V617F allele burden using a bead-based liquid assay with locked nucleic acid-modified oligonucleotide probes
    Shivarov, Velizar
    Ivanova, Milena
    Hadjiev, Evgueniy
    Naumova, Elissaveta
    LEUKEMIA & LYMPHOMA, 2011, 52 (10) : 2023 - 2026
  • [34] Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients
    Pearson, Stella
    Blance, Rognvald
    Yan, Fei
    Hsieh, Ya-Ching
    Geary, Bethany
    Amaral, Fabio M. R.
    Somervaille, Tim C. P.
    Kirschner, Kristina
    Whetton, Anthony D. D.
    Pierce, Andrew
    PLOS ONE, 2023, 18 (05):
  • [35] Is the JAK2 V617F Mutation a Hallmark for Different Forms of Thrombosis?
    Zerjavic, Katja
    Zagradisnik, Boris
    Herodez, Spela Stangler
    Lokar, Lidija
    Krasevac, Marjana Glaser
    Vokac, Nadja Kokalj
    ACTA HAEMATOLOGICA, 2010, 124 (01) : 49 - 56
  • [36] Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders
    Sazawal, Sudha
    Bajaj, Jyoti
    Chikkara, Sunita
    Jain, Sonal
    Bhargava, Rahul
    Mahapatra, Manoranjan
    Saxena, Renu
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2010, 132 (04) : 423 - 427
  • [37] JAK2 V617F down-modulates MPL
    Fleischman, Angela G.
    Tyner, Jeffrey W.
    BLOOD, 2012, 119 (20) : 4579 - 4580
  • [38] Clinical Performance of JAK2 V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory Evaluation of Screening and Quantitation Methods
    Cankovic, Milena
    Whiteley, Lisa
    Hawley, Robert C.
    Zarbo, Richard J.
    Chitale, Dhananjay
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 132 (05) : 713 - 721
  • [39] Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients
    Muendlein, Axel
    Gasser, Klaus
    Kinz, Elena
    Stark, Nicole
    Leiherer, Andreas
    Rein, Philipp
    Saely, Christoph H.
    Grallert, Harald
    Peters, Annette
    Drexel, Heinz
    Lang, Alois H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (03) : 295 - 301
  • [40] The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms
    Borowczyk, Martyna
    Wojtaszewska, Marzena
    Lewandowski, Krzysztof
    Gil, Lidia
    Lewandowska, Maria
    Lehmann-Kopydlowska, Agata
    Kroll-Balcerzak, Renata
    Balcerzak, Andrzej
    Iwola, Malgorzata
    Michalak, Michal
    Komarnicki, Mieczyslaw
    THROMBOSIS RESEARCH, 2015, 135 (02) : 272 - 280
12345